Why kidneys fail in autosomal dominant polycystic kidney disease

Nature Reviews Nephrology

Volumn 7, Issue 10, 2011, Pages 556-566

  Grantham, Jared J ^a   Mulamalla, Sumanth ^a   Swenson Fields, Katherine I ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE;

DISEASE COURSE; GLOMERULUS FILTRATION RATE; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; URETER OBSTRUCTION;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MAGNETIC RESONANCE IMAGING; NEPHRONS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENAL INSUFFICIENCY; URETERAL OBSTRUCTION;

EID: 84860420284     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.109     Document Type: Review

References (113)

1. Hildebrandt, F., Attanasio, M. & Otto, E. Nephronophthisis: disease mechanisms of a ciliopathy. J. Am. Soc. Nephrol. 20, 23-35 (2009).
2. Harris, P. C. & Torres, V. E. Polycystic kidney disease. Annu. Rev. Med. 60, 321-337 (2009).
3. Grantham, J. J., Geiser, J. L. & Evan, A. P. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 31, 1145-1152 (1987). (Pubitemid 17069098)
4. Cuppage, F. E., Huseman, R. A., Chapman, A. & Grantham, J. J. Ultrastructure and function of cysts from human adult polycystic kidneys. Kidney Int. 17, 372-381 (1980). (Pubitemid 10101596)
5. Carone, F. A., Bacallao, R. & Kanwar, Y. S. The pathogenesis of polycystic kidney disease. Histol. Histopathol. 10, 213-221 (1995).
6. Ishikawa, I.; et al. Long-term natural history of acquired cystic disease of the kidney. Ther. Apher. Dial. 14, 409-416 (2010).
7. Grantham, J. J. Acquired cystic kidney disease. Kidney Int. 40, 143-152 (1991).
8. Dalgaard, O. Z. Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Acta Med. Scand. Suppl. 328, 1-255 (1957).
9. Grantham, J. J. Clinical practice. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477-1485 (2008).
10. Franz, K. A. & Reubi, F. C. Rate of functional deterioration in polycystic kidney disease. Kidney Int. 23, 526-529 (1983). (Pubitemid 13117121)
11. Gabow, P. A. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 329, 332-342 (1993). (Pubitemid 23210687)
12. Gabow, P. A.; et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 41, 1311-1319 (1992).
13. Welling, L. W. & Grantham, J. J. in Renal Pathology: with Clinical and Functional Correlations Vol. 2 (eds Tisher, C. C. & Brenner, B. M.) 1323-1354 (J. B. Lippencott, Philadelphia, 1994).
14. Zeier, M.; et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 42, 1259-1265 (1992).
15. Meijer, E.; et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 1091-1098 (2010).
16. Gabow, P. A.; et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int. 35, 675-680 (1989). (Pubitemid 19051769)
17. Chapman, A. B., Johnson, A. M., Gabow, P. A. & Schrier, R. W. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 5, 1349-1354 (1994). (Pubitemid 24977120)
18. Grantham, J. J.; et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122-2130 (2006). (Pubitemid 43736612)
19. Kistler, A. D.; et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int. 75, 235-241 (2009).
20. Sise, C.; et al. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int. 58, 2492-2501 (2000).
21. King, B. F., Reed, J. E., Bergstralh, E. J., Sheedy, P. F. 2nd & Torres, V. E. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 11, 1505-1511 (2000). (Pubitemid 30483467)
22. Antiga, L.; et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin. J. Am. Soc. Nephrol. 1, 754-760 (2006).
23. Klahr, S.; et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 5, 2037-2047 (1995).
24. Welling, L. W. & Grantham, J. J. Physical properties of isolated perfused renal tubules and tubular basement membranes. J. Clin. Invest. 51, 1063-1075 (1972).
25. Madsen, K. M. & Brenner, B. M. in Anthology of the Kidney Vol. 1 (eds Tisher, C. C. & Brenner, B. M.) 661-698 (J. B. Lippencott, Philadelphia, 1994).
26. Taal, M. W. & Brenner, B. M. in Brenner & Rector's The Kidney Vol. 1 (ed. Brenner, B. M.) 783-819 (Saunders, Philadelphia, 2008).
27. Bae, K. T. & Grantham, J. J. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat. Rev. Nephrol. 6, 96-106 (2010).
28. Muskhelishvili, L., Latendresse, J. R., Kodell, R. L. & Henderson, E. B. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J. Histochem. Cytochem. 51, 1681-1688 (2003). (Pubitemid 37475441)
29. Happé, H.; et al. Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum. Mol. Genet. 18, 2532-2542 (2009).
30. Chang, M. Y.; et al. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol. Dial. Transplant. 21, 2078-2084 (2006). (Pubitemid 44295032)
31. Grantham, J. J. 1992 Homer Smith Award. Fluid secretion, cellular proliferation, and the pathogenesis of renal epithelial cysts. J. Am. Soc. Nephrol. 3, 1841-1857 (1993).
32. Gardner, K. D. Jr. Composition of fluid in twelve cysts of a polycystic kidney. N. Engl. J. Med. 281, 985-988 (1969).
33. Huseman, R., Grady, A., Welling, D. & Grantham, J. Macropuncture study of polycystic disease in adult human kidneys. Kidney Int. 18, 375-385 (1980). (Pubitemid 10015219)
34. Verani, R. R. & Silva, F. G. Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: a histochemical study. Mod. Pathol. 1, 457-463 (1988).
35. Sullivan, L. P., Wallace, D. P. & Grantham, J. J. Epithelial transport in polycystic kidney disease. Physiol. Rev. 78, 1165-1191 (1998). (Pubitemid 28491952)
36. Wallace, D. P. Cyclic AMP-mediated cyst expansion. Biochim. Biophys. Acta doi:10.1016/j.bbadis.2010.11.005.
37. Woo, D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N. Engl. J. Med. 333, 18-25 (1995).
38. Nagao, S.; et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 17, 2220-2227 (2006). (Pubitemid 44141912)
39. Park, J. Y.; et al. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol. 8, 12 (2007).
40. Ibrahim, S. Increased apoptosis and proliferative capacity are early events in cyst formation in autosomal-dominant, polycystic kidney disease. ScientificWorldJournal 7, 1757-1767 (2007). (Pubitemid 350277602)
41. Goilav, B., Satlin, L. M. & Wilson, P. D. Pathways of apoptosis in human autosomal recessive and autosomal dominant polycystic kidney diseases. Pediatr. Nephrol. 23, 1473-1482 (2008).
42. Edelstein, C. L. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1219-1226 (2008).
43. Goilav, B. Apoptosis in polycystic kidney disease. Biochim. Biophys. Acta doi:10.1016/j.bbadis.2011.01.006.
44. Thomson, R. B.; et al. Histopathological analysis of renal cystic epithelia in the Pkd2WS25/-mouse model of ADPKD. Am. J. Physiol. Renal Physiol. 285, F870-F880 (2003). (Pubitemid 37288633)
45. Brill, S. R.; et al. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc. Natl Acad. Sci. USA 93, 10206-10211 (1996). (Pubitemid 26314600)
46. Davidow, C. J., Maser, R. L., Rome, L. A., Calvet, J. P. & Grantham, J. J. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int. 50, 208-218 (1996). (Pubitemid 26323715)
47. Belibi, F. A.; et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 66, 964-973 (2004). (Pubitemid 39120999)
48. Gattone, V. H. 2nd, Maser, R. L., Tian, C., Rosenberg, J. M. & Branden, M. G. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev. Genet. 24, 309-318 (1999). (Pubitemid 29211795)
49. Wang, X., Gattone, V. 2nd, Harris, P. C. & Torres, V. E. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J. Am. Soc. Nephrol. 16, 846-851 (2005). (Pubitemid 41710293)
50. Wang, X., Wu, Y., Ward, C. J., Harris, P. C. & Torres, V. E. Vasopressin directly regulates cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 102-108 (2008).
51. Reeders, S. T.; et al. Prenatal diagnosis of autosomal dominant polycystic kidney disease with a DNA probe. Lancet 2, 6-8 (1986).
52. Bae, K. T.; et al. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin. J. Am. Soc. Nephrol. 4, 719-725 (2009).
53. Cadnapaphornchai, M. A., Masoumi, A., Strain, J. D., McFann, K. & Schrier, R. W. Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin. J. Am. Soc. Nephrol. 6, 369-376 (2011).
54. Grantham, J. J., Chapman, A. B. & Torres, V. E. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 1, 148-157 (2006).
55. Grantham, J. J., Cook, L. T., Wetzel, L. H., Cadnapaphornchai, M. A. & Bae, K. T. Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin. J. Am. Soc. Nephrol. 5, 889-896 (2010).
56. Harris, P. C.; et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 17, 3013-3019 (2006). (Pubitemid 44707761)
57. Grantham, J. J. & Levine, E. Acquired cystic disease: replacing one kidney disease with another. Kidney Int. 28, 99-105 (1985). (Pubitemid 15246691)
58. Chapman, A. B., Johnson, A., Gabow, P. A. & Schrier, R. W. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 323, 1091-1096 (1990). (Pubitemid 20370729)
59. Chapman, A. B.; et al. The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 5, 102-109 (2010).
60. Seeman, T.; et al. Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr. Nephrol. 11, 592-596 (1997). (Pubitemid 27397089)
61. Fick-Brosnahan, G. M., Tran, Z. V., Johnson, A. M., Strain, J. D. & Gabow, P. A. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int. 59, 1654-1662 (2001). (Pubitemid 32366566)
62. Evan, A. P., Gardner, K. D. Jr & Bernstein, J. Polypoid and papillary epithelial hyperplasia: a potential cause of ductal obstruction in adult polycystic disease. Kidney Int. 16, 743-750 (1979). (Pubitemid 10063528)
63. Clapp, W. L. & Tisher, C. C. in Renal Pathology with Clinical and Functional Correlations Vol. 1 (eds Tisher, C. C. & Brenner, B. M.) 67-89 (J. B. Lippencott, Philadelphia, 1989).
64. Torra, R.; et al. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J. Am. Soc. Nephrol. 7, 2142-2151 (1996). (Pubitemid 27468243)
65. Hateboer, N.; et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353, 103-107 (1999). (Pubitemid 29088079)
66. Torra, R.; et al. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am. J. Kidney Dis. 36, 728-734 (2000).
67. Brown, J. H.; et al. Missense mutation in sterile α motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J. Am. Soc. Nephrol. 16, 3517-3526 (2005). (Pubitemid 46211272)
68. Tanner, G. A., Gretz, N., Connors, B. A., Evan, A. P. & Steinhausen, M. Role of obstruction in autosomal dominant polycystic kidney disease in rats. Kidney Int. 50, 873-886 (1996). (Pubitemid 26302676)
69. Tanner, G. A. & Evan, A. P. Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int. 36, 1050-1060 (1989). (Pubitemid 20049212)
70. Chevalier, R. L. Obstructive nephropathy: lessons from cystic kidney disease. Nephron 84, 6-12 (2000). (Pubitemid 30066136)
71. Chevalier, R. L., Forbes, M. S. & Thornhill, B. A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 75, 1145-1152 (2009).
72. Klahr, S. & Morrissey, J. Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int. Suppl. S105-S112 (2003). (Pubitemid 37315516)
73. Chevalier, R. L., Thornhill, B. A., Forbes, M. S. & Kiley, S. C. Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy. Pediatr. Nephrol. 25, 687-697 (2010).
74. Torres, V. E.; et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int. 42, 364-373 (1992).
75. Torres, V. E.; et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 112-120 (2007).
76. Maser, R. L., Vassmer, D., Magenheimer, B. S. & Calvet, J. P. Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J. Am. Soc. Nephrol. 13, 991-999 (2002) (Pubitemid 34274095)
77. Menon, V.; et al. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 7-13 (2011).
78. Torres, V. E. Polycystic liver disease. Contrib. Nephrol. 115, 44-52 (1995).
79. Nagao, S.; et al. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int. 63, 427-437 (2003). (Pubitemid 36126789)
80. Schaefer, L.; et al. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat. Kidney Int. 49, 75-81 (1996). (Pubitemid 26024229)
81. Gardner, K. D. Jr, Burnside, J. S., Elzinga, L. W. & Locksley, R. M. Cytokines in fluids from polycystic kidneys. Kidney Int. 39, 718-724 (1991).
82. Wallace, D. P.; et al. Periostin induces proliferation of human autosomal dominant polycystic kidney cells through αV-integrin receptor. Am. J. Physiol. Renal Physiol. 295, F1463-F1471 (2008).
83. Zheng, D.; et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 14, 2588-2595 (2003). (Pubitemid 37169344)
84. Meijer, E.; et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am. J. Kidney Dis. 56, 883-895.
85. Cowley, B. D. Jr, Ricardo, S. D., Nagao, S. & Diamond, J. R. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int. 60, 2087-2096 (2001). (Pubitemid 33070452)
86. Ishikawa, I.; et al. Long-term natural history of acquired cystic disease of the kidney. Ther. Apher. Dial. 14, 409-416 (2010).
87. Shannon, M. B., Patton, B. L., Harvey, S. J. & Miner, J. H. A hypomorphic mutation in the mouse laminin α5 gene causes polycystic kidney disease. J. Am. Soc. Nephrol. 17, 1913-1922 (2006). (Pubitemid 44036175)
88. Mangos, S.; et al. The ADPKD genes pkd1a/b and pkd2 regulate extracellular matrix formation. Dis. Model Mech. 3, 354-365 (2010).
89. Wu, G.; et al. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93, 177-188 (1998). (Pubitemid 28180852)
90. Nishio, S.; et al. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J. Clin. Invest. 115, 910-918 (2005). (Pubitemid 40489395)
91. Jiang, S. T.; et al. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. Am. J. Pathol. 168, 205-220 (2006).
92. Thivierge, C.; et al. Overexpression of PKD1 causes polycystic kidney disease. Mol. Cell Biol. 26, 1538-1548 (2006). (Pubitemid 43202577)
93. Piontek, K., Menezes, L. F., Garcia-Gonzalez, M. A., Huso, D. L. & Germino, G. G. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat. Med. 13, 1490-1495 (2007). (Pubitemid 350224245)
94. Park, E. Y.; et al. Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice. J. Biol. Chem. 284, 7214-7222 (2009).
95. Raphael, K. L.; et al. Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells. Kidney Int. 75, 626-633 (2009).
96. Hassane, S.; et al. Elevated TGFβ-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J. Pathol. 222, 21-31 (2010).
97. Boulter, C.; et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc. Natl Acad. Sci. USA 98, 12174-12179 (2001). (Pubitemid 32959846)
98. Baert, L. Hereditary polycystic kidney disease (adult form): a microdissection study of two cases at an early stage of the disease. Kidney Int. 13, 519-525 (1978). (Pubitemid 8373078)
99. Qian, F., Watnick, T. J., Onuchic, L. F. & Germino, G. G. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87, 979-987 (1996). (Pubitemid 26427982)
100. Gattone, V. H. 2nd & Grantham, J. J. Understanding human cystic disease through experimental models. Semin. Nephrol. 11, 617-631 (1991).
101. Gattone, V. H. 2nd et al. Autosomal recessive polycystic kidney disease in a murine model. A gross and microscopic description. Lab. Invest. 59, 231-238 (1988).
102. Lantinga-van Leeuwen, I. S.; et al. Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum. Mol. Genet. 16, 3188-3196 (2007).
103. Rankin, C. A., Grantham, J. J. & Calvet, J. P. C-fos expression is hypersensitive to serum-stimulation in cultured cystic kidney cells from the C57BL/6J-cpk mouse. J. Cell Physiol. 152, 578-586 (1992).
104. Takakura, A.; et al. Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum. Mol. Genet. 18, 2523-2531 (2009).
105. Patel, V.; et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum. Mol. Genet. 17, 1578-1590 (2008). (Pubitemid 351737162)
106. Boor, P., Ostendorf, T. & Floege, J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat. Rev. Nephrol. 6, 643-656 (2010).
107. Zeisberg, M. & Neilson, E. G. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 21, 1819-1834 (2010).
108. Meijer, E.; et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol. Dial. Transplant. 26, 2445-2453 (2011).
109. Walz, G.; et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830-840 (2010).
110. Serra, A. L.; et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820-829 (2010).
111. Grantham, J. J., Bennett, W. M. & Perrone, R. D. mTOR inhibitors and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 364, 286-287; author reply 287-289 (2011).
112. Braun, W. E. mTOR inhibitors and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 364, 287; author reply 287-288 (2011).
113. Levey, A. S. & Stevens, L. A. mTOR inhibitors and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 364, 287; author reply 287-289 (2011).